fda warning letters glp-1 compounding october 2025 Warns 25 Firms Over Compounded Claims FDA unleashes warning letters to

Subcutaneous Injection Sites Abdomen 2+ inches from navel, rotating around stomach area Outer Thighs Mid to upper outer thigh regions Upper Arms Back of upper arm (harder to self-inject) Upper Outer Quadrant of Buttocks Upper outer region for easy self-administration Proper Injection Technique Technique involves: Clean injection site with alcohol swab Pinch skin to create fold Insert needle at 45-90 angle into subcutaneous tissue Inject slowly and steadily Remove needle and apply gentle pressure without rubbing Critically: Rotate injection sites to never use the same spot consecutively Important Injection Considerations GHK-Cu specifically can cause injection site reactions ranging from mild to moderate pain due to copper peptide irritation, with possible redness, swelling, or knot formation lasting several days

GHRP-6s ~2030 minutes) sustains IGF-1 elevation for longer, making it preferable for anabolic signaling studies where consistency matters more than peak amplitude

GraphPad Prism 9.0.0 was utilized for graph production

BraganzaOBednerPHttmannKvon StadenEFriedmanASeifertGet al

A subsequent, double blind placebo controlled study did not confirm the benefits observed in the Sechi trial (Hauser RA, et al